aclarion inc - ACON

ACON

Close Chg Chg %
4.46 0.15 3.36%

Closed Market

4.61

+0.15 (3.36%)

Volume: 53.70K

Last Updated:

Dec 31, 2025, 4:00 PM EDT

Company Overview: aclarion inc - ACON

ACON Key Data

Open

$4.45

Day Range

4.42 - 4.68

52 Week Range

0.50 - 129.61

Market Cap

$2.99M

Shares Outstanding

671.37K

Public Float

671.34K

Beta

1.43

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1,602.94

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

111.16K

 

ACON Performance

1 Week
 
-14.66%
 
1 Month
 
-26.52%
 
3 Months
 
-37.41%
 
1 Year
 
-90.46%
 
5 Years
 
N/A
 

ACON Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About aclarion inc - ACON

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

ACON At a Glance

Aclarion, Inc.
8181 Arista Place
Broomfield, Colorado 80021
Phone 1-833-275-2266 Revenue 45.72K
Industry Packaged Software Net Income -6,992,927.00
Sector Technology Services Employees 6
Fiscal Year-end 12 / 2025
View SEC Filings

ACON Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 26.857
Price to Book Ratio 1.839
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.144
Enterprise Value to Sales 16.717
Total Debt to Enterprise Value N/A

ACON Efficiency

Revenue/Employee 7,620.667
Income Per Employee -1,165,487.833
Receivables Turnover 2.495
Total Asset Turnover 0.02

ACON Liquidity

Current Ratio 0.611
Quick Ratio 0.611
Cash Ratio 0.402

ACON Profitability

Gross Margin -507.55
Operating Margin -12,057.235
Pretax Margin -15,293.778
Net Margin -15,293.778
Return on Assets -305.151
Return on Equity -5,777.798
Return on Total Capital -720.878
Return on Invested Capital -5,777.798

ACON Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Aclarion Inc - ACON

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
60.29K 60.44K 75.40K 45.72K
Sales Growth
+23.93% +0.25% +24.75% -39.36%
Cost of Goods Sold (COGS) incl D&A
195.42K 208.92K 238.40K 277.80K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
189.37K 143.62K 162.67K 193.14K
Depreciation
12.98K 4.50K 1.56K 1.40K
Amortization of Intangibles
176.39K 139.12K 161.11K 191.74K
COGS Growth
-0.85% +6.91% +14.11% +16.53%
Gross Income
(135.13K) (148.48K) (163.00K) (232.07K)
Gross Income Growth
+8.97% -9.88% -9.78% -42.38%
Gross Profit Margin
-224.13% -245.64% -216.16% -507.55%
2021 2022 2023 2024 5-year trend
SG&A Expense
2.82M 5.41M 4.71M 5.28M
Research & Development
724.73K 1.07M 873.34K 888.77K
Other SG&A
2.09M 4.35M 3.84M 4.39M
SGA Growth
+20.99% +92.10% -12.93% +12.05%
Other Operating Expense
- - 800 800
-
Unusual Expense
- (373.51K) (573.46K) 944.68K
EBIT after Unusual Expense
(2.58M) (5.56M) (4.30M) (6.46M)
Non Operating Income/Expense
(1.89M) 1.32K (560) 268
Non-Operating Interest Income
- - 2.51K 318
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
476.48K 1.51M 608.29K 535.47K
Interest Expense Growth
+205.32% +216.39% -59.65% -11.97%
Gross Interest Expense
476.48K 1.51M 608.29K 535.47K
Interest Capitalized
- - - -
-
Pretax Income
(4.95M) (7.07M) (4.91M) (6.99M)
Pretax Income Growth
-6.80% -42.79% +30.52% -42.38%
Pretax Margin
-8,210.53% -11,694.45% -6,513.41% -15,293.78%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(4.95M) (7.07M) (4.91M) (6.99M)
Minority Interest Expense
- - - -
-
Net Income
(4.95M) (7.07M) (4.91M) (6.99M)
Net Income Growth
-6.80% -42.79% +30.52% -42.38%
Net Margin Growth
-8,210.53% -11,694.45% -6,513.41% -15,293.78%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(4.95M) (7.07M) (4.91M) (6.99M)
Preferred Dividends
- 1.01M 415.52K 59.67K
Net Income Available to Common
(5.96M) (7.48M) (4.91M) (7.05M)
EPS (Basic)
-120035.1096 -177396.3288 -79782.6888 -7480.215
EPS (Basic) Growth
-8.55% -47.79% +55.03% +90.62%
Basic Shares Outstanding
49.6179588199 42.18884 61.5597567753 942.8388015907
EPS (Diluted)
-120035.1096 -177396.3288 -79782.6888 -7480.215
EPS (Diluted) Growth
-8.55% -47.79% +55.03% +90.62%
Diluted Shares Outstanding
49.6179588199 42.18884 61.5597567753 942.8388015907
EBITDA
(2.76M) (5.42M) (4.71M) (5.32M)
EBITDA Growth
+35.44% -96.01% +13.02% -12.87%
EBITDA Margin
-4,585.14% -8,964.91% -6,250.74% -11,634.83%

Snapshot

Average Recommendation BUY Average Target Price 22.00
Number of Ratings 1 Current Quarters Estimate -2.79
FY Report Date 03 / 2026 Current Year's Estimate -13.71
Last Quarter’s Earnings -3.60 Median PE on CY Estimate N/A
Year Ago Earnings -15.13 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 N/A
Mean Estimate -2.79 -3.24 -13.71 N/A
High Estimates -2.79 -3.24 -13.71 N/A
Low Estimate -2.79 -3.24 -13.71 N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Aclarion Inc in the News